Clinical Trial Detail

NCT ID NCT03746041
Title A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Rochester
Indications

myelodysplastic syndrome

chronic myelomonocytic leukemia

Therapies

Abaloparatide + Bevacizumab

Age Groups: senior adult

No variant requirements are available.